14159, L.P.
CIK 1551138 · last filed 2019-02-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$688.52M
Companies
8
Total Filings
22
Lifetime Open-Market Net
$899.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 92,042 | $117.39 | $10.80M | $0 | 6 | 2019-02-27 |
| Aceragen, Inc. (IDRA) Delisted | Director | 251,992 | $7.22 | $1.82M | $0 | 2 | 2019-01-04 |
| ACAD | Director | 24,667,110 | $25.43 | $627.28M | $459.53M | 2 | 2018-09-24 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 204,452 | — | — | $223.55M | 7 | 2017-10-03 |
| XOMA | Director | 870,308 | $40.17 | $34.96M | -$92.18M | 2 | 2014-12-10 |
| Seagen Inc. (SGEN) Delisted | Director | 3,949,073 | $228.74 | $903.31M | $113.02M | 1 | 2013-12-16 |
| BCRX | 10%+ Owner | 1,642,513 | $9.42 | $15.47M | $50.00M | 1 | 2013-08-02 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 207,820 | — | — | $146.01M | 1 | 2012-07-13 |
Recent Filings · Page 3 of 3
22 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-11-14 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +619,002 | $16.91M | EDGAR |
| 2012-07-13 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Buy (P) | +3,544,000 | $146.01M | EDGAR |
Showing 21–22 of 22
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.